- Stocks
- Pharma & Healthcare
- Global Health
Global Health share price
NSE: MEDANTAPharma & HealthcareMedical Care Facilities
Global Health at a glance
Global Health (NSE: MEDANTA) closed at ₹1,215.10 on 22 Oct 2026, down 1.65% on the day. With a market capitalisation of ₹32,216 Cr, it ranks 256th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 58.9× trailing earnings, against a return on equity of 14.0% in FY26. Over the past year the share price has fallen 10.1%. Its 52-week range is ₹956.00 (30 Mar 2026) to ₹1,544.00 (27 Aug 2026); the last close is 21.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹1,304 Cr (+26.5% year on year) and net profit ₹157 Cr (−1.1%), on a consolidated basis. Promoters held 33.00% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹32,216 CrRank 256 on NSE
- P/E (trailing)
- 58.9×
- Price to book
- 6.52×FY26
- EPS (TTM)
- ₹20.70to Q1 FY27
- ROE
- 14.0%FY26
- ROCE
- 15.1%FY26
- Debt to equity
- 0.3FY26
- Net profit margin
- 12.6%FY26
- Book value / share
- ₹147.44FY26
- 52-week high
- ₹1,544.0027 Aug 2026
- 52-week low
- ₹956.0030 Mar 2026
- 1-year return
- −10.1%
- RSI (14-day)
- 27.7
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.65% | −5.1% | −19.3% | −10.3% | −10.1% |
Global Health quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹957 Cr | ₹943 Cr | ₹931 Cr | ₹1,031 Cr | ₹1,099 Cr | ₹1,121 Cr | ₹1,159 Cr | ₹1,304 Cr |
| Revenue YoY | +13.3% | +13.3% | +15.2% | +19.7% | +14.9% | +18.8% | +24.5% | +26.5% |
| Net profit | ₹131 Cr | ₹143 Cr | ₹101 Cr | ₹159 Cr | ₹158 Cr | ₹95 Cr | ₹142 Cr | ₹157 Cr |
| Net profit YoY | +4.5% | +15.6% | −20.4% | +49.6% | +21.1% | −33.5% | +39.7% | −1.1% |
| Net margin | 13.7% | 15.1% | 10.9% | 15.4% | 14.4% | 8.5% | 12.2% | 12.1% |
| EPS | ₹4.87 | ₹5.32 | ₹3.77 | ₹5.92 | ₹5.89 | ₹3.54 | ₹5.36 | ₹5.91 |
Global Health financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹2,167 Cr | ₹2,694 Cr | ₹3,275 Cr | ₹3,692 Cr | — |
| Operating profit | ₹281 Cr | ₹449 Cr | ₹627 Cr | ₹697 Cr | — |
| Net profit | ₹196 Cr | ₹326 Cr | ₹478 Cr | ₹481 Cr | — |
| EPS (₹) | ₹8.00 | ₹13.00 | ₹18.00 | ₹18.00 | — |
| Cash from operations | ₹311 Cr | ₹645 Cr | ₹612 Cr | ₹624 Cr | — |
| Total debt | ₹768 Cr | ₹737 Cr | ₹283 Cr | ₹264 Cr | ₹1,127 Cr |
| Shareholders' equity | ₹1,616 Cr | ₹2,428 Cr | ₹2,906 Cr | ₹3,386 Cr | ₹3,962 Cr |
Global Health shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 33.03% | 33.01% | 33.01% | 33.01% | 33.01% | 33.00% |
| Foreign institutions | 11.76% | 11.54% | 11.40% | 10.53% | 10.15% | 9.46% |
| Domestic institutions | 11.93% | 12.20% | 12.98% | 14.00% | 14.76% | 16.89% |
| Non-institutions | 43.28% | 43.19% | 42.55% | 42.40% | 42.00% | 40.56% |
Global Health vs peers
The listed Pharma & Healthcare companies nearest to Global Health by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| NHNarayana Hrudayalaya | ₹1,691.90 | −2.21% | −2.8% | ₹34,602 Cr | 42.4 | 17.8% |
| EMCUREEmcure Pharmaceuticals | ₹1,759.20 | +0.09% | +31.6% | ₹33,812 Cr | 145.1 | 18.7% |
| MEDANTAGlobal Health | ₹1,215.10 | −1.65% | −10.1% | ₹32,216 Cr | 58.9 | 14.0% |
| LALPATHLABDr. Lal Path Labs | ₹1,838.50 | +0.46% | +16.3% | ₹30,907 Cr | 58 | 20.1% |
| WOCKPHARMAWockhardt | ₹1,889.60 | +0.46% | +38.2% | ₹30,150 Cr | 144.8 | 4.3% |
| SAILIFESai Life Sciences | ₹1,396.80 | −0.06% | +63.2% | ₹29,633 Cr | 85.1 | 8.0% |
| KIMSKrishna Institute of Medical Sciences | ₹671.30 | +0.04% | −5.5% | ₹28,080 Cr | 111.9 | 18.0% |
Ask anything about Global Health
Pivot answers on the live chart with evidence you can check, and tests strategies against MEDANTA's own history. Try: “Why has MEDANTA moved over the last three months?” · “Backtest a 50-day moving-average crossover on MEDANTA over five years” · “Compare MEDANTA with NH on margins and valuation”
Frequently asked questions about Global Health
What is the share price of Global Health today?
Global Health (NSE: MEDANTA) last closed at ₹1,215.10 on 22 Oct 2026. Its 52-week high is ₹1,544.00 and its 52-week low is ₹956.00.
What is the market cap of Global Health?
Global Health's market capitalisation is ₹32,216 Cr (₹32,216 Cr) at the 22 Oct 2026 close, ranking 256th among the NSE companies Pivot tracks.
What is the P/E ratio of Global Health?
Global Health trades at a trailing P/E of 58.9. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 111.9.
What is the ROE and ROCE of Global Health?
Return on equity was 14.0% in FY26 and return on capital employed was 15.1% in FY26 (consolidated figures).
Is Global Health a debt-free company?
No. Global Health's debt-to-equity ratio was 0.3 in FY26, with total debt of ₹1,127 Cr.
What were Global Health's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Global Health reported revenue of ₹1,304 Cr, +26.5% year on year, and net profit of ₹157 Cr, −1.1% year on year.
How has Global Health stock performed over the last year?
Global Health's share price has fallen 10.1% over the past year, −10.3% over three months and −19.3% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Global Health?
As of 30 Jun 2026: promoters 33.00%, foreign institutions 9.46%, domestic institutions 16.89%, non-institutions 40.56%.
Who are Global Health's competitors?
The listed Pharma & Healthcare companies closest to Global Health by market cap are Narayana Hrudayalaya, Emcure Pharmaceuticals, Dr. Lal Path Labs, Wockhardt, Sai Life Sciences and Krishna Institute of Medical Sciences.
Is Global Health a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Global Health's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MEDANTA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text